Earnings summaries and quarterly performance for Artiva Biotherapeutics.
Executive leadership at Artiva Biotherapeutics.
Fred Aslan
Detailed
Chief Executive Officer
CEO
CH
Christopher Horan
Detailed
Chief Technical Operations Officer
HR
Heather Raymon
Detailed
Senior Vice President of Research and Early Development
JB
Jennifer Bush
Detailed
Chief Operating Officer
NK
Neha Krishnamohan
Detailed
Chief Financial Officer
SB
Subhashis Banerjee
Detailed
Chief Medical Officer
Board of directors at Artiva Biotherapeutics.
Research analysts covering Artiva Biotherapeutics.
Recent press releases and 8-K filings for ARTV.
Artiva Therapeutics Provides Update on AlloNK Cell Therapy for Autoimmune Diseases and Financial Runway
ARTV
New Projects/Investments
Guidance Update
- Artiva Therapeutics (ARTV) is advancing AlloNK, an off-the-shelf, non-genetically modified NK cell therapy for autoimmune diseases, designed to offer cell therapy efficacy with biologic-like tolerability.
- In autoimmune clinical trials, 32 patients have been treated, showing a "really clean safety profile" with no CRS, ICANS, or GVHD reported, and only one patient hospitalized for infection.
- The therapy achieves deep B cell depletion, with no detectable B cells in every treated patient using a high sensitivity assay, and B cell reconstitution typically begins around six months with naive or transitional B cells.
- The company expects to release clinical data for rheumatoid arthritis (RA) and FDA feedback on a pivotal trial in the first half of next year (2026), aiming for a 50% ACR50 response in the refractory RA population.
- Artiva reported a cash balance of $123 million as of the end of September (2025), providing a financial runway into Q2 2027. The projected cost of goods sold (COGS) per dose ranges from $3,000 to $12,000.
Nov 18, 2025, 12:00 PM
Artiva Therapeutics Provides Update on AlloNK Clinical Development and Financials
ARTV
New Projects/Investments
Guidance Update
- Artiva Therapeutics is developing AlloNK, an off-the-shelf cell therapy for autoimmune diseases, aiming to deliver cell therapy activity with a biologics-like tolerability profile.
- In ongoing clinical trials for autoimmune diseases, Artiva has treated 32 patients across five indications (RA, myositis, scleroderma, lupus, and Sjogren's) as of the cutoff date.
- The therapy has shown a clean safety profile with no CRS, ICANS, or GVHD observed, and only one patient out of 32 was hospitalized for an infection, which was treated with IV antibiotics. The safety profile is considered comparable to biologics like rituximab.
- Translational data demonstrated deep B cell depletion in every treated patient using a high-sensitivity assay, with B cell reconstitution around six months predominantly consisting of naive or transitional B cells, similar to AutoCAR T's mechanism of action.
- Artiva plans to release clinical data in Rheumatoid Arthritis (RA) and feedback from the FDA regarding a pivotal trial in the first half of next year (2026). The company reported a cash balance of $123 million as of the end of September (2025), providing a runway into Q2 2027.
Nov 18, 2025, 12:00 PM
Artiva Provides AlloNK Program Update and Clinical Timelines
ARTV
New Projects/Investments
Product Launch
Guidance Update
- Artiva's AlloNK is an allogeneic NK cell therapy that utilizes monoclonal antibodies for targeting, which allows it to avoid the runaway Cytokine Release Syndrome (CRS) typically associated with T-cell therapies.
- The manufacturing process for AlloNK is highly scalable, yielding thousands of 1 billion cell vials from a single umbilical cord unit, with a shelf life of three to four years. The projected cost of goods (COGS) is $1,000 or less per billion cell vial, enabling potential for very high gross margins.
- Artiva is exclusively focused on autoimmune disease, prioritizing rheumatoid arthritis (RA) as its lead indication, for which it recently received Fast-Track designation.
- The company plans to release clinical response data for at least 15 RA patients, many with at least six months of follow-up, in the first half of 2026. The goal is to achieve 12-24 month durability and a 50% ACR 50 response in 50% of patients who have failed at least two targeted therapies.
- AlloNK's safety profile is differentiated, showing no CRS or ICANS, and manageable lymphodepletion, allowing for administration in a community setting, similar to an IV biologic.
Nov 12, 2025, 4:30 PM
Artiva Biotherapeutics Provides AlloNK Autoimmune Data Update and Financials
ARTV
Guidance Update
New Projects/Investments
- Artiva Biotherapeutics announced a strong financial position with $123 million in cash and a projected runway into Q2 2027.
- The company presented initial safety and translational data for AlloNK in 32 autoimmune patients, highlighting a low hospitalization rate of only one patient out of 32, suggesting the potential for outpatient management.
- AlloNK has demonstrated consistent deep B-cell depletion, and the company aims to achieve a 50% or higher ACR 50 response in refractory rheumatoid arthritis (RA) patients.
- Artiva plans to release clinical response data from over 15 refractory RA patients in the first half of 2026 and engage in discussions with the FDA regarding a potential pivotal trial in refractory RA.
Nov 12, 2025, 1:00 PM
Artiva Biotherapeutics Provides AlloNK Autoimmune Disease Update
ARTV
New Projects/Investments
Guidance Update
- Artiva Biotherapeutics reported initial safety and translational data for its lead product, AlloNK, in autoimmune diseases, having dosed over 100 patients across oncology and autoimmune disease.
- The company has $123 million in cash, providing a runway into Q2 2027.
- Initial safety data from 32 autoimmune patients treated with AlloNK in combination with anti-CD20 monoclonal antibodies showed no cell therapy-related toxicities (CRS, ICANS, GVHD, or hypogammaglobulinemia), a low rate of infections, and a low hospitalization rate, suggesting the regimen can be managed in an outpatient setting.
- AlloNK, when combined with cyclophosphamide (CY), fludarabine (FLU), and a monoclonal antibody, has demonstrated complete and deep B-cell depletion in autoimmune patients, with reconstituting B-cells showing a predominantly naive or transitional phenotype.
- Artiva plans to share clinical response data in over 15 refractory RA patients in the first half of 2026 and engage in discussions with the FDA regarding a potential pivotal trial in refractory RA, targeting 50% or higher ACR 50 response in this patient population.
Nov 12, 2025, 1:00 PM
Artiva Biotherapeutics Provides AlloNK Autoimmune Disease Update and Financial Outlook
ARTV
New Projects/Investments
Guidance Update
- Artiva Biotherapeutics announced its Q3 financial results, reporting $123 million in cash and a cash runway into Q2 2027.
- The company provided initial safety and translational data for its lead product, AlloNK, in autoimmune diseases, noting that over 100 patients have been dosed across oncology and autoimmune disease.
- Initial safety data from 32 autoimmune patients treated with AlloNK showed the regimen was well-tolerated with a low hospitalization rate during the immunosuppressed period.
- Translational data demonstrated that AlloNK combined with an anti-CD20 monoclonal antibody achieved B-cell depletion in all 23 patients with sufficient follow-up as of October 1, 2025.
- Artiva has selected refractory rheumatoid arthritis (RA) as its lead indication and plans to discuss pivotal trial design with the FDA in H1 2026, with clinical response data for over 15 refractory RA patients expected in H1 2026.
Nov 12, 2025, 1:00 PM
Artiva Biotherapeutics Announces Positive Initial AlloNK Clinical Data in Autoimmune Disease
ARTV
New Projects/Investments
- Artiva Biotherapeutics, Inc. (ARTV) announced positive initial safety and translational data from ongoing clinical trials of AlloNK® (AB-101) in combination with anti-CD20 monoclonal antibody for autoimmune disease, based on data from 32 patients as of October 1, 2025.
- The treatment regimen was generally well tolerated, with no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported, demonstrating feasibility for administration in outpatient and community settings.
- Consistent and complete B-cell depletion was observed in all analyzed patients by Day 13 of treatment.
- Artiva plans to share initial clinical response data and engage in FDA regulatory interactions in the first half of 2026 to align on the pivotal trial design for AlloNK in refractory rheumatoid arthritis (RA).
Nov 12, 2025, 12:22 PM
Artiva Biotherapeutics Reports Q3 2025 Financial Results and AlloNK Updates
ARTV
Earnings
Guidance Update
CFO Change
- Artiva Biotherapeutics reported cash, cash equivalents, and investments of $123.0 million as of September 30, 2025, which is expected to fund operations into Q2 2027.
- For the third quarter ended September 30, 2025, the company recorded a net loss of $21.5 million, with research and development expenses totaling $17.6 million and general and administrative expenses at $5.3 million.
- In October 2025, the FDA granted Fast Track Designation to AlloNK for refractory rheumatoid arthritis (RA), which has been prioritized as the lead indication.
- Initial clinical response data for AlloNK in refractory RA is anticipated in 1H 2026, along with planned FDA interactions to align on potential pivotal trial design.
- Neha Krishnamohan will transition from her role as Chief Financial Officer and EVP, Corporate Development at the end of December 2025, moving to an advisory role as the company conducts a search for her replacement.
Nov 12, 2025, 12:05 PM
Artiva Biotherapeutics Announces Q1 2025 Financial and Clinical Trial Updates
ARTV
Earnings
New Projects/Investments
- Q1 2025 Financial Highlights: Reported a net loss of $20.3 million and maintained $166.0 million in cash, cash equivalents, and investments, which is expected to fund operations into Q2 2027.
- Clinical Trial Developments: Initiated regulatory submissions and launched a global basket trial exploring AlloNK+rituximab across refractory autoimmune diseases, marking the first U.S. company-sponsored trial for rheumatoid arthritis and Sjögren’s disease.
- Increased Investments in R&D: Reported research and development expenses of $17.1 million, alongside increased general & administrative costs, reflecting ongoing investment in innovative cell therapy programs.
May 8, 2025, 12:00 AM
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Business Updates
ARTV
Earnings
Board Change
New Projects/Investments
- Financial Position: Artiva reported full year 2024 results with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, which is expected to fund operations through at least the end of 2026.
- Business Developments: The company highlighted strategic updates including an expanded board and bolstered leadership, along with upcoming milestones for its AlloNK® program — with initial autoimmune data expected in H1 2025 and updated NHL clinical results to be presented in 2025.
Mar 24, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more